GO
Loading...

Government Agencies

More

  • WASHINGTON, Dec 24- The U.S. Commodity Futures Trading Commission said on Wednesday it had fined MF Global Holdings Ltd for wrongdoing during the collapse of the futures brokerage, but will continue its lawsuit against the firm's former chief, Jon Corzine. A federal judge in Manhattan approved a settlement in which the company will pay a $100 million fine and be...

  • NEW YORK/ LONDON, Dec 24- Gold fell near a three-week low on Wednesday as the latest piece of strong U.S. economic data fed the view that the Federal Reserve may bring forward the timing of a hike in U.S. interest rates. U.S. Labor Department data showed initial claims for state unemployment benefits dropped for the fourth straight week. Spot gold, initially supported...

  • Dec 24- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.. Memantine is the active ingredient in Actavis' Namenda, while donepezil is the active ingredient in Pfizer Inc's Aricept. Dublin, Ireland- based Actavis said it expects to launch Namzaric in...

  • Actavis, Adamas win FDA approval for Alzheimer's drug Wednesday, 24 Dec 2014 | 8:20 AM ET

    Dec 24- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.. The drug, Namzaric, is designed to treat moderate-to-severe dementia in Alzheimer's patients who are stabilized with other drugs. Namzaric combines two ingredients in drugs often...

  • LONDON, Dec 24- The rouble slipped on Wednesday after ratings agency Standard& Poor's warned it could downgrade Russia in the new year, while robust U.S. growth data boosted bets on the Federal Reserve raising rates soon, subduing broader emerging markets. The rouble dropped 0.2 percent against the dollar in the wake of S&P warning that Russia's sovereign rating...

  • FDA to ease ban on blood donations by gay men Wednesday, 24 Dec 2014 | 12:06 AM ET

    But many medical groups, including the American Medical Association, say the policy is no longer supported by science. Australia, Japan, the U.K. and many other countries previously moved to a one-year period. The agency will recommend the switch in draft guidelines early next year and move to finalize them after taking comments from the public, FDA officials...

  • *Nikkei advances on back of record day on Wall Street. TOKYO, Dec 24- Japanese stocks rallied on Wednesday after Wall Street raced to a record closing-high on the back of data showing decisive strength in the U.S. economy, which lifted risk appetite and backed last week's upbeat assessment by the Federal Reserve. On Wall Street the Dow closed above 18,000 for the...

  • Obama selects longtime NRC attorney as chairman Tuesday, 23 Dec 2014 | 7:00 PM ET

    WASHINGTON— President Barack Obama has selected a 33- year veteran of the Nuclear Regulatory Commission, Stephen G. Burns, to serve as its chairman. Burns replaces Allison Macfarlane, who is stepping down to take a position at George Washington University. He has also served a stint as head of legal affairs for the Organization for Economic Cooperation and...

  • FDA approves Novo Nordisk's injection for obesity Tuesday, 23 Dec 2014 | 5:14 PM ET

    Dec 23- The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans. Saxenda's rivals include Vivus Inc's Qsymia and Arena Pharmaceuticals Inc's Belviq, which are taken orally. A study showed that half the patients given Saxenda lost at least 5...

  • "The FDA has carefully examined and considered the available scientific evidence relevant to its blood donor deferral policy for men who have sex with men, including the results of several recently completed scientific studies and recent epidemiologic data," FDA Commissioner Margaret Hamburg said in a statement. The FDA said the move aligns the policy for...

  • FDA clears Novo Nordisk's weight loss drug Saxenda Tuesday, 23 Dec 2014 | 4:29 PM ET

    NEW YORK— The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. The FDA approved liraglutide in 2010 as a treatment for type 2 diabetes, and Novo Nordisk sells it under the name Victoza as a treatment for that condition. It cleared Vivus Inc.' s Qsymia and Arena Pharmaceuticals Inc.' s Belviq in 2012 and granted...

  • Scientific evidence shows the move will not create risks for the nation's blood supply, the FDA said. The FDA said the move aligns the policy for gay men with that for other men and women who are at increased risk for HIV infection. The FDA said it will issue draft guidance on the policy, hopefully early in 2015. It would then review the comments and issue final...

  • What?! 80,000 pounds of bacon recalled because... Tuesday, 23 Dec 2014 | 1:44 PM ET

    Florida company Abe's Finest Meats recalled more than 80,000 pounds of sliced bacon in Florida and Georgia due to a labeling issue.

  • FDA going after sellers of pure caffeine powder Tuesday, 23 Dec 2014 | 3:04 AM ET

    The FDA warned consumers to avoid pure powdered caffeine this summer after the death of an Ohio teen. Since the FDA doesn't have the legal authority to just pull such a substance off the shelves, the agency is in the process of building a legal case against those who are marketing it in bulk in an attempt to persuade them to stop. Michael Taylor, FDA's deputy...

  • WASHINGTON, Dec 22- U.S. Federal Communications Commission on Monday once again paused its review of the proposed $45 billion merger of Comcast Corp and Time Warner Cable Inc, citing delays in getting documents from Time Warner Cable. The FCC said it learned this month that Time Warner Cable had improperly withheld more than 7,000 documents the regulators had...

  • FDA approves new melanoma drug from Bristol-Myers Monday, 22 Dec 2014 | 4:23 PM ET

    WASHINGTON— The Food and Drug Administration granted accelerated approval Monday to a new drug from Bristol-Myers Squibb to treat the deadliest form of skin cancer. Since 2011, the FDA has approved seven new drugs for the form of skin cancer, including Opdivo. FDA regulators cleared the drug for patients who have previously been treated with an older...

  • WASHINGTON, Dec 22- U.S. Federal Communications Commission on Monday paused until January 12 its informal 180- day countdown for the review of the proposed $45 billion merger of Comcast Corp and Time Warner Cable Inc over delays in document submission.

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • FDA approves Bristol-Myer's skin cancer drug Monday, 22 Dec 2014 | 2:32 PM ET

    Dec 22- The U.S. Food and Drug Administration granted an accelerated approval to Bristol-Myers Squibb Co's drug for an advanced form of skin cancer. The drug, Opdivo, inhibits the action of the protein PD-1, which prevents the body's immune system from attacking melanoma tumors. The FDA's approval comes well before its scheduled review date of March 30.

  • NEW YORK— Eli Lilly will sell its heartworm treatment for dogs to garner U.S. approval for its $5.4 billion acquisition of the animal health division belonging to Norvartis. The Federal Trade Commission said Monday that it is requiring the sale of Eli Lilly's Sentinel heartworm products because the Novartis deal would reduce competition and lead to higher...